Jason Garland Sells 733 Shares of Repligen (NASDAQ:RGEN) Stock

Repligen Corporation (NASDAQ:RGEN) CFO Jason Garland sold 733 shares of the company’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $145.00, for a total transaction of $106,285.00. Following the transaction, the chief financial officer owned 19,359 shares in the company, valued at approximately $2,807,055. The trade was a 3.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Repligen Trading Up 1.2%

RGEN opened at $147.01 on Friday. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.20 and a quick ratio of 7.78. The company has a market cap of $8.29 billion, a price-to-earnings ratio of 163.35, a price-to-earnings-growth ratio of 2.83 and a beta of 1.09. The firm has a 50 day simple moving average of $122.84 and a 200 day simple moving average of $135.54. Repligen Corporation has a fifty-two week low of $100.99 and a fifty-two week high of $175.77.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The firm had revenue of $194.25 million for the quarter, compared to analysts’ expectations of $192.05 million. During the same period last year, the firm earned $0.39 earnings per share. The business’s revenue for the quarter was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. On average, sell-side analysts anticipate that Repligen Corporation will post 1.99 earnings per share for the current year.

Institutional Investors Weigh In On Repligen

Several large investors have recently modified their holdings of the business. Iron Triangle Partners LP bought a new stake in Repligen during the 3rd quarter worth approximately $36,091,000. Hudson Bay Capital Management LP bought a new position in Repligen in the third quarter valued at approximately $2,807,000. Massachusetts Financial Services Co. MA bought a new position in Repligen in the fourth quarter valued at approximately $199,176,000. Cinctive Capital Management LP acquired a new position in shares of Repligen in the third quarter valued at approximately $3,398,000. Finally, Royce & Associates LP boosted its holdings in shares of Repligen by 66.1% in the third quarter. Royce & Associates LP now owns 148,658 shares of the biotechnology company’s stock valued at $19,871,000 after buying an additional 59,136 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Roth Mkm began coverage on Repligen in a report on Friday, April 17th. They issued a “buy” rating and a $160.00 price objective for the company. Wall Street Zen lowered Repligen from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. HC Wainwright upped their price target on Repligen from $180.00 to $208.00 and gave the company a “buy” rating in a research note on Monday, March 23rd. Royal Bank Of Canada started coverage on shares of Repligen in a research report on Thursday, May 14th. They issued an “outperform” rating and a $160.00 price target on the stock. Finally, Rothschild & Co Redburn set a $160.00 price objective on shares of Repligen and gave the company a “buy” rating in a report on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $164.64.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.